et al. FDA approval summary: pembrolizumab for recurrent locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma expressing PD-L1. Oncologist 24, 103–109 (2019). Article CAS PubMed Google Scholar Shitara, K. et al. Pembrolizumab versus paclitaxel for previously treated, ...
Yang CW. Prognostic predictors of technique and patient survival in elderly southeast Asian patients undergoing continuous ambulatory peritoneal dialysis. Int J Clin Pract. 2009;63(2):254–60.https://doi.org/10.1111/j.1742-1241.2006.01216.x. ...
问运行pandas pd.test()有哪些依赖项？EN当程序员当的越久，接触的越多，就会越“迷茫”。像我，...
number of PD-L1-positive exosomes and the level of PD-L1 expression in the tumor tissue, although tumor-specific exosomes could not be distinguished in the present study. However, Chen et al. (2018) recently proposed that exosomal PD-L1 is associated with an anti-PD-1 response in melanoma,...
Narayan P, Wahby S, Gao JJ et al (2020) FDA approval summary: Atezolizumab plus paclitaxel protein-bound for the treatment of patients with advanced or metastatic TNBC whose tumors express PD-L1. Clin Cancer Res 26:2284–2289 ArticleCASGoogle Scholar ...
Reporting Summary Source data Source Data Fig. 1 Statistical source data. Source Data Fig. 2 Statistical source data. Source Data Fig. 3 Statistical source data. Source Data Table 1 Statistical source data. Source Data Table 2 Statistical source data. Source Data Table 3 Statistical source data...
Radiotherapy displays unique antitumor synergism with immune checkpoint inhibitors, which is indicated by high pathological complete response (pCR) rates from single-arm trials of locally advanced rectal cancer (LARC). Here we test the efficacy and safety of the radiation–immune checkpoint inhibitor com...
Data distribution was assumed to be normal, but this was not formally tested. Reporting summary Further information on research design is available in the Nature Portfolio Reporting Summary linked to this article.Data availability RNA-sequencing data that support the findings of this study have been ...
C-Jun, a critical component of AP-1, exerts essential functions in various tumors, including melanoma, and is believed to be a druggable target for cancer therapy. Unfortunately, no effective c-Jun inhibitors are currently approved for clinical use. The
A. et al. EAU guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2013 guidelines. Eur. Urol. 65, 778–792 (2014). Article Google Scholar Hall, E. J. & Giaccia, A. J. Radiobiology for the Radiologist 6th edn (Lippincott Williams & Wilkins, 2006). Google ...